検索
Gilead Sciences Inc
GILDウォッチリストに追加
125.160USD
+0.110+0.09%
終値 06/24, 16:00（ET）15分遅れの株価
155.39B時価総額
16.88直近12ヶ月PER
詳細情報 Gilead Sciences Inc 企業名
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, COVID-19, cancer and inflammation. It is focused on discovering, developing and delivering medicines to address unmet medical needs in virology, oncology and other therapeutic areas. Its portfolio of marketed products includes Biktarvy, Genvoya, Descovy, Complera/Eviplera, Symtuza, Truvada, Stribild, Sunlenca, Epclusa, Vemlidy, Harvoni, Viread, Livdelzi, Veklury, Yescarta, Tecartus, Trodelvy, AmBisome, and Letairis. Its product candidates include Bulevirtide, Lenacapavir, Axicabtagene ciloleucel, Sacituzumab govitecan-hziy, and others. It also develops the HB-400 program and the HB-500 program. It develops therapies that are intended to provide functional cures for hepatitis B virus and human immunodeficiency virus-1. It operates in more than 35 countries worldwide.
Gilead Sciences Incの企業情報
企業コードGILD
会社名Gilead Sciences Inc
上場日Jan 22, 1992
最高経営責任者「CEO」O'Day (Daniel P)
従業員数17600
証券種類Ordinary Share
決算期末Jan 22
本社所在地333 Lakeside Dr
都市FOSTER CITY
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号94404-1147
電話番号16505743000
ウェブサイトhttps://www.gilead.com/
企業コードGILD
上場日Jan 22, 1992
最高経営責任者「CEO」O'Day (Daniel P)
Gilead Sciences Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Daniel P. O'Day
Mr. Daniel P. O'Day
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
--
--
Dr. Sandra J. Horning, M.D.
Dr. Sandra J. Horning, M.D.
Independent Director
Independent Director
--
--
Mr. Javier J. Rodriguez
Mr. Javier J. Rodriguez
Independent Director
Independent Director
--
--
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Dr. Jeffrey A. (Jeff) Bluestone, Ph.D.
Independent Director
Independent Director
--
--
詳細を見る
会社名
会社名/ポジション
ポジション
株式保有
変動額
Ms. Johanna Mercier
Ms. Johanna Mercier
Chief Commercial Officer
Chief Commercial Officer
124.23K
-1.24%
Dr. Jacqueline K. Barton, Ph.D.
Dr. Jacqueline K. Barton, Ph.D.
Independent Director
Independent Director
27.20K
+4.21%
Mr. Anthony (Tony) Welters, J.D.
Mr. Anthony (Tony) Welters, J.D.
Lead Independent Director
Lead Independent Director
12.89K
+8.89%
Ms. Kelly A. Kramer
Ms. Kelly A. Kramer
Independent Director
Independent Director
1.34K
--
Mr. Harish Manwani
Mr. Harish Manwani
Independent Director
Independent Director
--
--
Mr. Andrew D. (Andy) Dickinson
Mr. Andrew D. (Andy) Dickinson
Chief Financial Officer
Chief Financial Officer
--
--
よくある質問
Gilead Sciences Incの上位5名の株主は誰ですか？
Gilead Sciences Incの上位5名の株主は以下のとおりです。Ms. Johanna Mercier
Gilead Sciences Inc（GILD）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Gilead Sciences Incの株式を保有している機関は3702社あり、保有株式の総市場価値は約1.14Bで、全体の92.19%を占めています。2025Q4と比較して、機関の持ち株は-2548741.00増加しています。
Gilead Sciences Incの最大の収益源は何ですか？
2026Q1において、Biktarvy部門がGilead Sciences Incにとって最大の収益を生み出しており、その金額は14.33Bで、全収益の48.68%を占めています。
